Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Date
2021
Author
Ghia, Paolo
Furman, Richard R.
Chanan-Khan, Asher
Kater, Arnon P.
Byrd, John C.
Hamdy, Ahmed
Patel, Priti
Higgins, Kara
Sohoni, Sophia
Jurczak, Wojciech
Hillmen, Peter
Izumi, Raquel
Rothbaum, Wayne
Robak, Tadeusz
Stilgenbauer, Stephan
Lepretre, Stephane
Seymour, John F.
Pinilla-Ibarz, Javier
Mato, Anthony
Garcia-Marco, Jose A.
Kay, Neil
Illes, Arpad
YENEREL, Mustafa Nuri
O'Brien, Susan
Metadata
Show full item record
Abstract
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).
URI
http://hdl.handle.net/20.500.12627/185162
https://doi.org/10.1200/jco.21.01210
Collections